Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
ConclusionNo evident price drops of included brand-name OMPs were observed around MEE and differences in purchase prices are modest in the selected Western European countries. Results were not subject to significance testing. More robust data are needed to strengthen negotiations with suppliers.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
More News: Denmark Health | Economics | France Health | Germany Health | Health Management | Netherlands Health